Gregg Pressman, MD, is a professor of medicine in the division of cardiology, Jefferson Einstein Philadelphia Hospital, Thomas Jefferson University.

Low-Grade Diastolic Dysfunction Still Harms Left Ventricle Function, With Gregg Pressman, MD

Right ventricular end-diastolic volume and right ventricular ejection fraction (RVEF) have been heavily associated with left ventricular diastolic function, with even grade 1 

 associated with a substantial drop in RVEF.

Left heart failure (HF) has long been known to be a common cause of right HF. Increases in left atrial pressure result in reduced pulmonary artery compliance and increased right ventricular afterload, and left ventricular diastolic function is a critical determinant of left atrial pressure. Given this connection, DD was widely expected to affect right ventricle size and function.

“We know that, when the left ventricle becomes stiff and a patient develops heart failure, the pressure of the heart rises, the pressure in the lungs rise, and the right ventricle can be enlarged and weakened,” Gregg Pressman, MD, professor of medicine in the division of cardiology, Jefferson Einstein Philadelphia Hospital, Thomas Jefferson University, told 

 in an exclusive interview. “What is less clear, and what we studied, is whether stiffening of the left side of the heart by itself causes abnormal function on the right half of the heart, even if the patient doesn’t have clinical signs and symptoms of heart failure.”

Pressman and colleagues enrolled 370 patients in the trial, all of whom were undergoing clinically indicated echocardiograms and had a 3D assessment of the right ventricle. Inpatients and outpatients were included; patients were excluded if they were younger than 18 years, had nongroup 2 

 by World Health Organization classification, nonsinus rhythm at the time of echocardiography, or suboptimal 3D echocardiographic images.

After imaging, patients were separated into groups based on diastolic function grade. The final data were based on the 2025 ASE algorithm, categorizing patients as having normal diastolic function or grades 1, 2, or 3 DD. Investigators compared 3D-derived right ventricle end-diastolic volume (RVEDV) and indexed RVEDV (RVEDVi) across diastolic grades, followed by comparing linear measurements of the right ventricle and the ratios of basal right ventricle diastolic dimension, mid-right ventricle diastolic dimension, and right ventricle diastolic longitudinal dimension.

A regression analysis was then conducted to determine whether diastolic grade was an independent predictor of RVEDV and RVEF, controlling for age, sex, race, body surface area, and estimated systolic pulmonary artery pressure.

Ultimately, for 21 subjects, the auto right ventricle software could not provide volumetric measurements. For another 22, it could not provide TAPSE or right ventricle linear dimensions. For the remainder, RVEDV and RVEDVi were similar between patients with normal diastolic function and grade 1 DD. However, grades 2 and 3 showed substantial increases in both measures of right ventricle diastolic size. Similarly, basal and midcavity dimensions were similar between normal and grade 1 DD, but increased for grade 2 and 3. However, longitudinal dimension showed no significant relationship with diastolic function grade.

RVEF also showed a substantial decrease across diastolic function groups, irrespective of age, sex, race, body surface area, and systolic pulmonary arterial pressure. Notably, even grade 1 DD showed a significant decrease in RVEF compared to normal; indexed left and right atrial volumes were similar, but reservoir strain of each atrium was decreased in patients with grade 1 DD.

Ultimately, Pressman and colleagues determined that left ventricular DD can produce right ventricular enlargement and cause right heart dysfunction. They attribute this in part to the backward effects of elevated left arterial pressure on the pulmonary vasculature, which are transmitted to the right heart. The trial also highlights the risk of even lesser degrees of left ventricular DD to the right heart.

“Right now, we’re at an interesting time in cardiology – this type of heart failure, which is due to stiffening, finally has some effective treatments,” Pressman said. “For years, we did not have such treatments, and it’s an open question whether applying those treatments to patients who have stiffening but have not yet developed clinical heart failure might prevent enlargement and weakening of the right half of the heart.”

Editor’s Note: Pressman reports no relevant disclosures.

Almani MU, Romero AJ, Akuna E, et al. Impact of left ventricular diastolic function on right ventricular size and function. 

Thomas L, Marwick TH, Popescu BA, Donal E, Badano LP. Left Atrial Structure and Function, and Left Ventricular Diastolic Dysfunction: JACC State-of-the-Art Review. 

Videos

Pressman discusses his recent study highlighting the interplay between right ventricular end-diastolic volume and ejection fraction and the left ventricle’s health.

News

news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.

Clinical

clinical page is a resource for content on every specialty, disease, and topic available on our medical news site.

Cardiology

Cardiology condition center page is a comprehensive resource for clinical news and insights on cardiovascular and cardiometabolic diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for heart disease and cardiovascular events, as well as associated diabetes, renal failure, and more...

Structural Heart Disease

Strategic Alliance Partnership

Fernando Magro, MD, PhD, is head of clinical pharmacology at University Hospital São João.

From Induction to Year 4: Mirikizumab’s Lasting Impact in Ulcerative Colitis

Long-term findings from the LUCENT clinical program continue to strengthen the case for mirikizumab (Omvoh) as a potential disease-modifying therapy in moderately-to-severely active ulcerative colitis (UC).

Data presented at the 21st Congress of European Crohn’s and Colitis Congress (ECCO) demonstrate the p19-directed interleukin (IL)-23 monoclonal antibody’s sustained efficacy and safety through 212 weeks of continuous treatment across the LUCENT-1 (induction), LUCENT-2 (maintenance), and LUCENT-3 (open-label extension) trials.

Mirikizumab was approved for the treatment of UC in 2023 based on LUCENT program data from a pair of trials, UC-1 , a 12-week induction study, and UC-2, a 40-week maintenance study. Most recently, the US Food and Drug Administration approved a single-injection, once-monthly maintenance regimen (200 mg/2 mL) of mirikizumab for subcutaneous use in adults with UC after demonstrating bioequivalence to the previously approved 2-injection regimen.

Study investigator Fernando Magro, MD, PhD, head of clinical pharmacology at University Hospital São João, noted that the LUCENT program’s design mirrors the real-world management of UC, allowing investigators to evaluate not only early response but durability and impact on hard clinical outcomes.

Preventing UC-related hospitalizations and surgeries is a key goal outlined in SPIRIT consensus recommendations for disease-modification trials. During LUCENT-1, patients randomized to intravenous mirikizumab 300 mg every 4 weeks demonstrated lower rates of UC-related hospitalizations and surgeries compared with placebo. Those who achieved clinical response at week 12 and continued on subcutaneous mirikizumab 200 mg every 4 weeks in LUCENT-2 maintained those reductions, with no UC-related hospitalizations or surgeries reported in the mirikizumab-treated group during maintenance.

Of note, the durability of benefit extended into LUCENT-3. Among 316 patients entering the open-label extension, representing 835 patient-years of exposure, a single UC-related hospitalization was reported over 3 years, corresponding to an exposure-adjusted incidence rate of 0.1 per 100 patient-years. No UC-related surgeries were observed. Taken together, Magro says these results suggest sustained suppression of disease activity over 4 years of continuous treatment.

“It is amazing that we are changing the outcome and the natural history of ulcerative colitis with mirikizumab,” he said.

Magro additionally emphasized that early achievement of endoscopic and histo-endoscopic mucosal improvement after induction was closely linked to improved 1-year outcomes. Patients who reached remission at 1 year experienced stability over time, with no reported hospitalizations or surgeries through 4 years. Such durability, Magro noted, signals more than short-term symptom control—it suggests modification of the disease course itself.

The concept of “disease clearance,” encompassing endoscopic remission, histologic remission, and absence of symptoms, further underscores this shift, with roughly 60% of patients achieving this deep remission at 1 year and many maintaining it long term.

Given the significant morbidity associated with colectomy and the profound impact hospitalizations and surgery have on quality of life, Magro says sustained reductions in these outcomes represent a meaningful advance.

Editors’ note: Magro reports relevant disclosures with Abbvie, Arena, Biogen, Bristol-Myers Squibb, Falk, Ferring, Hospira, Janssen, Laboratórios Vitoria, Pfizer, Lilly, Merck Sharp & Dohme, Sandoz, Takeda, UCB, and Vifor.

Magro F, Ananthakrishnan A, Kobayashi T, et al. Mirikizumab treatment decreases Ulcerative Colitis-related surgery and hospitalisation rates: 4-year LUCENT studies results. Presented at 21st Congress of European Crohn’s and Colitis Congress (ECCO), February 18–21, 2026, Stockholm, Sweden.

Campbell P. FDA Approves Mirikizumab (Omvoh) for Ulcerative Colitis. HCPLive. October 26, 2023. Accessed February 26, 2026. 

https://www.hcplive.com/view/fda-approves-mirikizumab-omvoh-for-ulcerative-colitis

Livingston R. FDA Approves Single-Dose Formulation of Mirikizumab-mrkz for Ulcerative Colitis. HCPLive. October 27, 2025. Accessed February 26, 2026. 

https://www.hcplive.com/view/fda-approves-single-dose-formulation-of-mirikizumab-mrkz-for-ulcerative-colitis

4-year LUCENT data show mirikizumab reduces UC-related hospitalizations and surgeries, supporting durable remission and potential disease modification.

Gastroenterology

Gastroenterology condition center page is a comprehensive resource for clinical news and insights on digestive and GI conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for 

, IBS and IBD, Crohn's disease, and more.

Inflammatory Bowel Disease

On the HCPLive inflammatory bowel disease page, resources on the topics of medical news and expert insight into IBD can be found. Content includes articles, interviews, videos, podcasts, and breaking news on IBD and more.

Ulcerative Colitis

Ulcerative Colitis condition center page, resources on the topics of medical news and expert insight into colitis can be found. Content includes articles, interviews, videos, podcasts, and breaking news on UC research, treatment, and drug development.

LUCENT: Durable UC Control With Mirikizumab Through 4 Years, With Fernando Magro, MD, PhD

Discussing Promising New Findings on GLP-1 Use in Psoriasis Management

Discussing Promising New Findings on GLP-1 Use in Psoriasis Management, With Neal Bhatia, MD

 and obesity or overweight saw significant improvements in both conditions after using combined ixekizumab (Taltz) and tirzepatide (Zepbound) when compared to those using ixekizumab alone, according to recent data.

release of these data by Eli Lilly and Company

, resulting from the phase 3b TOGETHER-PsO trial (NCT06588283), the 

 editorial team interviewed Neal Bhatia, MD, the director of Clinical Dermatology at Therapeutics Clinical Research, to discuss these new data and their significance for weight loss and psoriasis.

“Mechanistically, it makes a lot of sense when you see what GLP-1 agonists do under the hood, with the immune mechanisms,” Bhatia said. “There's a lot of impact on [nuclear factor kappa B] as a neurotransmitter. Both interleukin 1 and interleukin 17 pathways are actually inhibited, or at least modulated, by their impact. Tumor necrosis factor…is suppressed just by trazepatide alone. Then you add just the active ingredient of what ixekizumab does as an IL-17 inhibitor.”

Bhatia touched on both the impacts of these 2 drugs in the open-label TOGETHER-PsO trial, highlighting their combined effects on skin clearance and weight loss in patients with psoriasis and elevated body mass index (BMI). He explained the synergistic impact of GLP-1 agonists on immune pathways, including NF-κB, interleukin (IL)-1, and tumor necrosis factor.

The investigators for TOGETHER-PsO had highlighted 27.1% of patients on the combination therapy achieved both PASI 100 and a minimum of 10% reduction in their weight, as opposed to only 5.8% of individuals treated with ixekizumab alone (

 Additionally, they had highlighted 40.6% of those in the combination arm achieved PASI 100 versus 29.0% in the monotherapy arm (

“[There are] a lot of opportunities to improve these patients along,” Bhatia explained. “Now, these are at 36 weeks, so this is a marathon, not a sprint, even though these drugs all work very fast.”

Bhatia noted future research on tirzepatide alone and its potential benefits in other diseases like hidradenitis suppurativa could be worth exploring. He also stressed the value of dermatologists and other clinicians integrating metabolic management into their practice to improve patient outcomes.

The quotes used in this summary were edited for the purposes of clarity.

Bhatia has reported serving as an advisor, consultant, and investigator for AbbVie, Almirall, Arcutis Biotherapeutics, Beiersdorf, Biofrontera, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant Sciences, EPI Health, Ferndale, Galderma, Incyte, ISDIN, Johnson & Johnson, La Roche-Posay, LEO Pharma, Lilly, Ortho Dermatologics, Pfizer, Regeneron Pharmaceuticals, Sanofi, Sun Pharma, and Verrica Pharmaceuticals.

Lilly's Taltz (ixekizumab) and Zepbound (tirzepatide) used together delivered superior efficacy in first-of-its-kind Phase 3b trial for adults with psoriasis and obesity or overweight. Eli Lilly. February 18, 2026. Accessed February 26, 2026. 

https://investor.lilly.com/news-releases/news-release-details/lillys-taltz-ixekizumab-and-zepbound-tirzepatide-used-together-0

Smith T. Ixekizumab, Tirzepatide Effective Together for Psoriasis and Obesity or Overweight. HCPLive. February 18, 2026. Accessed February 26, 2026. 

https://www.hcplive.com/view/ixekizumab-tirzepatide-effective-together-psoriasis-obesity-overweight

In this interview, Neal Bhatia, MD, highlights several key points about treating psoriasis and obesity via ixekizumab and tirzepatide.

Plaque Psoriasis

The HCPLive plaque psoriasis page is a resource for medical news and expert insights on psoriasis. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for psoriatic disease, and more.

Ryan Livingston joined the MJH Life Sciences team in March of 2025, shortly after graduating from TCNJ with a bachelor’s degree in English. He enjoys creative writing, reading, and scuba diving. He can be reached at rlivingston@mjhlifesciences.com.

Julio Rosenstock, MD | Image Credit: Velocity Clinical Research

On February 26, 2026, Eli Lilly announced detailed results from the phase 3 ACHIEVE-3 trial, the first head-to-head comparison of orforglipron and oral semaglutide in patients with 

Orforglipron is an investigational, once-daily small molecule non-peptide oral GLP-1 receptor agonist, which can be taken at any time of day without restrictions on food and water intake. Lilly is currently running phase 3 trials of orforglipron for both T2D and weight management in patients with obesity or overweight and ≥1 weight-related medical problem. Additionally, it is under investigation as a potential treatment for obstructive sleep apnea and hypertension in adults with obesity.

“ACHIEVE-3 gives us the first head-to-head comparison between 2 oral GLP-1 receptor agonist therapies in adults with type 2 diabetes, and the differences were clinically meaningful,” Julio Rosenstock, MD, director of the Dallas Diabetes Research Center at Medical City, professor of medicine at the University of Texas Southwestern Medical Center and lead investigator, said in a statement. “Orforglipron 12 mg and 36 mg doses outperformed oral semaglutide 7 mg and 14 mg diabetes-related doses on every key endpoint we measured, including A1C and weight loss, with improvements appearing as early as 4 weeks and sustained throughout the study.”

ACHIEVE-3 was a phase 3, randomized, open-label study conducted across 131 locations worldwide. Patients were eligible for inclusion if they had T2D with HbA1c ≥7% to ≤10.5%, as well as having been on stable diabetes treatment with metformin ≥1500 mg/day during the 90 days before screening. Patients were excluded if they had 

, were currently receiving or planning to receive treatment for diabetic retinopathy or macular edema, had a history of ketoacidosis or hyperosmolar state or coma within 6 months prior to screening, or had a New York Heart Association (NYHA) functional classification IV congestive heart failure, among other criteria.

A total of 1698 patients were enrolled in the trial and were randomly assigned to 4 treatment arms: orforglipron 12 mg and 36 mg, and oral semaglutide 7 mg and 14 mg. The primary endpoint was the change in A1C from baseline to week 52, with secondary endpoints including the change in weight from baseline and the percentage of achieving A1C <7%, ≤6.5%, and <5.7% at week 52.

Ultimately, orforglipron lowered A1C by 2.2% in the 36 mg arm and by 1.9% in the 12 mg arm, compared to reductions of 1.1% and 1.4% in semaglutide 7 mg and 14 mg, respectively. Additionally, participants receiving orforglipron saw a body weight reduction of 9.2% in the 36 mg arm and 6.7% in the 12 mg arm, compared to 3.7% and 5.3% in semaglutide 7 mg and 14 mg, respectively. Orforglipron also displayed clinically meaningful improvements from baseline across non-HDL and HDL cholesterol, VLDL cholesterol, total cholesterol, 

“The results of ACHIEVE-3 highlight the potential advantages of orforglipron over oral semaglutide for type 2 diabetes: greater A1C reduction, more weight loss, and the ability to take it without food or water timing restrictions – that’s a combination that could matter significantly to people managing their disease day in and day out,” Kenneth Custer, PhD, executive vice president and president of Lilly Cardiometabolic Health, said in a statement. “With global submissions underway and FDA action on obesity expected next quarter, we’re focused on making this option available as quickly as possible.”

Eli Lilly and Company. Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss compared to oral semaglutide in head-to-head type 2 diabetes trial published in The Lancet. February 26, 2026. Accessed February 26, 2026. 

https://investor.lilly.com/news-releases/news-release-details/lillys-oral-glp-1-orforglipron-delivered-superior-blood-sugar

Eli Lilly and Company. A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin (ACHIEVE-3). ClinicalTrials.gov Identifier: NCT06045221. Updated September 22, 2025. Accessed February 26, 2026. 

https://clinicaltrials.gov/study/NCT06045221

Articles

Lilly’s phase 3 ACHIEVE-3 trial provided the first head-to-head comparison of two oral GLP-1 receptor agonists in metformin-treated type 2 diabetes. In a 52-week, randomized open-label global study (n=1698), once-daily orforglipron (12 mg, 36 mg) produced larger HbA1c and weight reductions than oral semaglutide (7 mg, 14 mg), with separation evident by week 4 and maintained through week 52. Orforglipron also improved multiple cardiometabolic biomarkers and offers dosing without food or water timing restrictions.

Parent company Eli Lilly has released full data from ACHIEVE-3, indicating superior weight loss and A1C reductions with orforglipron 12 mg and 36 mg.

Endocrinology

The HCPLive endocrinology page is a comprehensive resource for clinical news and insights on endocrine system conditions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for diabetes, hormonal disease, and more.

Type 2 Diabetes

ACHIEVE-3: Orforglipron Achieves Superiority to Oral Semaglutide in Poorly Controlled T2D

Image Credit: US Food and Drug Administration

 accepted the supplemental New Drug Application (NDA) for olezarsen for the treatment of 

Announced by parent company Ionis Pharmaceuticals, the FDA has set a Prescription User Drug Fee Act (PDUFA) date of June 30, 2026. The sNDA submission is a result of positive results from the phase 3 CORE and CORE2 studies of olezarsen in 2025, during which olezarsen displayed substantial reductions in fasting triglyceride levels at 6 months and sustained it through 12 months.

“Current standard of care therapies for sHTG provide limited benefit, leaving people vulnerable to recurrent and debilitating acute pancreatitis attacks with serious, long-term health consequences,” Brett Monia, PhD, chief executive officer of Ionis, said in a statement. “The FDA’s Priority Review designation underscores the urgent need for additional treatment options and will enable us to bring olezarsen to patients as quickly as possible.”

Olezarsen is an investigative antisense oligonucleotide designed to lower apolipoprotein C-III (apoC-III) production by regulating triglyceride metabolism in the blood. This slows triglyceride clearance, as well as limiting the liver’s uptake of triglyceride-rich particles. Olezarsen has already been approved for chylomicronemia syndrome in the US and EU.

The CORE and CORE2 trials were both double-blind, randomized, placebo-controlled trials enrolling patients with sHTG and randomly assigning them in a 1:1:1 ratio to either olezarsen 50 mg, olezarsen 80 mg, or placebo monthly for 12 months. Both studies’ primary endpoint was percent change in triglyceride levels at 6 months, with secondary lipid endpoints including percent change in triglyceride levels at 12 months and in apoC-III, remnant cholesterol, and non-high-density lipoprotein (non-HDL) cholesterol at 6 and 12 months.

A total of 1061 patients were included across both trials, with 617 in CORE and 444 in CORE2. By 6 months, investigators recorded a placebo-adjusted, least-squares mean change in triglyceride levels from baseline of -62.9 percentage points in the olezarsen 50-mg group and -72.2 percentage points in the olezarsen 80-mg group during CORE. In CORE2, the olezarsen 50-mg arm saw a -49.2 percentage point mean change, while the olezarsen 80-mg group saw a -54.4 percentage point mean change (

Additionally, apoC-III, remnant cholesterol, and non-HDL cholesterol reductions were all greater among the olezarsen arms than with placebo. Acute pancreatitis incidence was lower with olezarsen than placebo (mean rate ratio, 0.15; 95% CI, 0.05-0.4; 

 <.001). Adverse event incidence was similar across both trial groups, and elevations in liver-enzyme levels and thrombocytopenia were more common among patients receiving 80 mg of olezarsen. A dose-dependent increase in the hepatic fat fraction was also recorded.

The FDA’s acceptance of olezarsen’s sNDA – and the assignment of priority review status – illustrate the magnitude of these trial results. Additionally, the FDA granted Breakthrough Therapy designation to olezarsen in November 2025, following the announcement of CORE and CORE2’s positive results.

“This milestone represents a significant step towards our goal of delivering the first-ever treatment shown to reduce the risk of potentially life-threatening acute pancreatitis attacks in people with sHTG,” Monia said.

Ionis Pharmaceuticals. Olezarsen sNDA accepted by the FDA for Priority Review for the treatment of severe hypertriglyceridemia (sHTG). 

. February 26, 2026. Accessed February 26, 2026. 

https://www.businesswire.com/news/home/20260226109569/en/Olezarsen-sNDA-accepted-by-the-FDA-for-Priority-Review-for-the-treatment-of-severe-hypertriglyceridemia-sHTG

Marston NA. Olezarsen Proves Efficacy in Severe Hypertriglyceridemia, With Nicholas Marston, MD. 

. November 18, 2025. Accessed February 26, 2026. 

https://www.hcplive.com/view/olezarsen-proves-efficacy-in-severe-hypertriglyceridemia-with-nicholas-marston-md

Marston NA, Bergmark BA, Alexander VJ, et al. Olezarsen for managing severe hypertriglyceridemia and pancreatitis risk. New England Journal of Medicine. 2026;394(5):429-441. 

FDA accepted Ionis’ supplemental NDA for olezarsen in severe hypertriglyceridemia with priority review and a PDUFA date of June 30, 2026, supported by phase 3 CORE/CORE2 data. The monthly antisense apoC-III inhibitor produced large, placebo-adjusted triglyceride reductions at 6 months with durability through 12 months, along with favorable changes in apoC-III and atherogenic lipid parameters. Acute pancreatitis events were reduced versus placebo. Safety was broadly comparable, though 80 mg showed more liver-enzyme elevations, thrombocytopenia, and dose-dependent hepatic fat increases.

The supplemental New Drug Application submission comes as a result of positive phase 3 data from the CORE and CORE2 trials or olezarsen in 2025.

Dyslipidemia

FDA News

FDA Accepts Olezarsen’s sNDA for Severe Hypertriglyceridemia, Grants Priority Review

Muthiah Vaduganathan, MD, MPH, is a cardiologist specializing in cardiorenal metabolism at Brigham and Women's Hospital in Boston, MA. Vaduganathan is a member of Practical Cardiology's advisory board and co-host of Don't Miss a Beat, a podcast presented by Inside Cardiology.

Why CKD screening lags despite aligned KDIGO, ADA and hypertension guidance—use eGFR plus UACR staging and EHR prompts to act earlier.

Video Series

Understanding the Link Between Early CKD Diagnosis and Cardiovascular Outcomes

CKD guidelines agree: use eGFR plus UACR for KDIGO staging, but screening lags—see how teams and EHRs close the gap.

Quality of Life Impact of Delayed CKD 

Timothy E. Dribin, from the division of emergency medicine, at Cincinnati Children’s Hospital Medical Center.

Expert panel identifies high agreement for multi-organ involvement, but uncertainty remains in moderate isolated skin or mucosal symptoms.

Anaphylaxis

The HCPLive anaphylaxis page is a comprehensive resource for clinical news and insights on acute allergic reactions. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for preventing anaphylaxis, and more.

Allergy

Allergy condition center page is a comprehensive resource for clinical news and insights on allergic and inflammatory diseases. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for food and seasonal allergies, as well as allergic asthma and related conditions.

International Consensus on Epinephrine Use, With Timothy E. Dribin, MD

Victoria Johnson joined the MJH Life Sciences in 2020 and has written for NeurologyLive, CGTLive, and now HCPLive. You can reach her at vjohnson@mjhlifesciences.com

Claims study suggests dry powder and soft mist COPD inhalers cut exacerbations versus MDIs, offering greener care without added safety risks.

COPD

COPD condition center page, resources on the topics of medical news and expert insight into chronic obstructive pulmonary disease can be found. Content includes articles, interviews, videos, podcasts, and breaking news on COPD research, treatment, and drug development.

Pulmonology

Infectious Disease condition center page is a comprehensive resource for clinical news and insights on respiratory health. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for asthma, COPD, interstitial lung disease, COVID-19, and more.

Lower-Carbon LAMA–LABA Inhalers Linked to Modest Reductions in COPD Exacerbation Risk

Joshua Rothman, MD, MS, is a clinical assistant professor in the department of pediatrics and Medical Director of Informatics Academic Pediatrics at the University of California San Diego.

New data show a >10% drop in newborn hepatitis B vaccination, raising concern for rising chronic infection and future liver cancer risk.

Hepatology

Hepatitis C

Hepatitis C page, resources on the topics of medical news and expert insight into HCV can be found. Content includes articles, interviews, videos, podcasts, and breaking news on hepatitis C virus research, treatment, and drug development.

Declining Hepatitis B Birth Dose Rates and the Risk to Long-Term Liver Health, With Joshua Rothman, MD, MS

This February episode of The Medical Sisterhood highlights key points on juggling work as a clinician and work as a mother.

The Medical Sisterhood, with Mona Shahriari, MD

The Medical Sisterhood, hosted by Mona Shahriari, MD, is a podcast dedicated to empowering female physicians by providing a platform for shared experiences, mentorship, and support. 

Each episode delves into the unique challenges women in medicine face, including work-life balance, leadership roles, and overcoming gender biases. Shahriari aims to inspire women to lead fulfilling professional and personal lives on their own terms through candid discussions and expert interviews. 

e as we foster a community where women can uplift and support each other in achieving their goals!

Dermatology

The HCPLive dermatology page is a resource for medical news and expert insights on skin disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for dermatologic conditions, and more.

The Medical Sisterhood: Physician Mom Burnout & Mental Health Strategies, With Jennifer Hsiao, MD

The FDA has approved proprietary desmopressin oral solution formulation ET-600 for the treatment of central diabetes insipidus in children.

FDA Approves ET-600 Desmopressin Acetate (Desmoda) for Central Diabetes Insipidus

Mary K Roberts, PhD is a Post Doctoral Researcher at the Leverhulme Centre for Demographic Science at the University of Oxford.

Willingness to pursue living kidney donation is shaped by relationships, health, and a multidisciplinary approach, not just finances.

Nephrology

The HCPLive nephrology page is a resource for medical news and expert insights on kidney disease. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments in nephrology, and more.

Living Donor Donation Works When Relationships Matter With Mary Roberts, PhD

Mark Creager, MD, is the director emeritus of the Heart and Vascular Center at Dartmouth University.

Creager discusses the accomplishments of the ACC and AHA’s joint PE clinical practice guideline while continuing to look to the future of the disease.

New Pulmonary Embolism Guidelines Highlight Progress, Encourage Research, With Mark Creager, MD

Andres Hurtado-Lorenzo, PhD, is VP of IBD Ventures and Translational Research at the Crohn’s & Colitis Foundation.

Hurtado-Lorenzo discusses trial data showing time-restricted feeding in Crohn’s disease results in weight loss, symptom improvement, and microbiome changes.

Latest News

Low-Grade Diastolic Dysfunction Still Harms Left Ventricle Function, With Gregg Pressman, MD

LUCENT: Durable UC Control With Mirikizumab Through 4 Years, With Fernando Magro, MD, PhD

Discussing Promising New Findings on GLP-1 Use in Psoriasis Management, With Neal Bhatia, MD

ACHIEVE-3: Orforglipron Achieves Superiority to Oral Semaglutide in Poorly Controlled T2D

FDA Accepts Olezarsen’s sNDA for Severe Hypertriglyceridemia, Grants Priority Review